Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis

MalaCards integrated aliases for Hepatitis:

Name: Hepatitis 12 75 29 55 6 43 44 15 38 72
Chronic Persistent Hepatitis 12 55 72
Chronic Hepatitis 12 15 17
Hepatitis, Chronic 44 72
Acute Hepatitis 12 72
Acute and Subacute Liver Necrosis 12
Acute/subac. Necrosis of Liver 12
Hepatitis Chronic 55
Hepatitis, Animal 72
Animal Hepatitis 12
Hepatitis a 72


External Ids:

Disease Ontology 12 DOID:2237
NCIt 50 C82978
SNOMED-CT 68 41889008 76783007
ICD10 33 K73 K73.0 K73.9
UMLS 72 C0001308 C0019158 C0019159 more

Summaries for Hepatitis

MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. Viruses cause most cases of hepatitis. The type of hepatitis is named for the virus that causes it; for example, hepatitis A, hepatitis B or hepatitis C. Drug or alcohol use can also cause hepatitis. In other cases, your body mistakenly attacks healthy cells in the liver. Some people who have hepatitis have no symptoms. Others may have Loss of appetite Nausea and vomiting Diarrhea Dark-colored urine and pale bowel movements Stomach pain Jaundice, yellowing of skin and eyes Some forms of hepatitis are mild, and others can be serious. Some can lead to scarring, called cirrhosis, or to liver cancer. Sometimes hepatitis goes away by itself. If it does not, it can be treated with drugs. Sometimes hepatitis lasts a lifetime. Vaccines can help prevent some viral forms.

MalaCards based summary : Hepatitis, also known as chronic persistent hepatitis, is related to hepatitis d and hepatitis a, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Hepatitis is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are Jak-Stat Signaling Pathway (sino) and Vitamin digestion and absorption. The drugs Alprostadil and Acarbose have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotype is mortality/aging.

Wikipedia : 75 Hepatitis is inflammation of the liver tissue. Some people have no symptoms whereas others develop... more...

Related Diseases for Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E

Diseases related to Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3482)
# Related Disease Score Top Affiliating Genes
1 hepatitis d 35.0 IFNA2 GPT
2 hepatitis a 33.8 SEPSECS HAVCR2 HAVCR1 GPT AFP
3 hepatitis c 33.8 SCARB1 KRT18 IFNL4 IFNAR2 IFNA2 IFNA1
4 autoimmune hepatitis 33.7 SEPSECS KRT8 GPT
5 viral hepatitis 33.7 SEPSECS KRT18 IFNA2 IFNA1 GPT AFP
6 hepatitis b 33.6 SLC10A1 RSF1 NR5A2 LAMTOR5 IFNAR2 IFNA2
7 hepatitis c virus 33.5 SCARB1 KRT8 KRT18 IFNL4 HAVCR2 GPT
8 liver cirrhosis 32.9 KRT8 KRT18 IFNA1 GPT AFP
9 liver disease 32.5 SEPSECS KRT8 KRT18 IFNA1 GPT AFP
10 cryoglobulinemia, familial mixed 32.2 IFNA2 IFNA1
11 viral infectious disease 31.8 IFNA2 IFNA1 GPT
12 opisthorchiasis 31.1 GPT AFP
13 cryptogenic cirrhosis 31.0 KRT8 KRT18
14 bile duct disease 30.9 SLC10A1 GPT AFP
15 discoid lupus erythematosus 30.3 IFNA2 IFNA1
16 transitional cell carcinoma 30.1 KRT8 KRT18 IFNA2
17 herpangina 29.5 IFNA2 IFNA1
18 lymphoepithelioma-like carcinoma 28.9 KRT8 KRT18
19 hepatic veno-occlusive disease 12.7
20 hepatic venoocclusive disease with immunodeficiency 12.7
21 hepatic lipase deficiency 12.7
22 hepatic encephalopathy 12.7
23 alcoholic hepatitis 12.7
24 hepatitis e 12.6
25 congenital hepatic fibrosis 12.6
26 hepatic adenomas, familial 12.5
27 renal-hepatic-pancreatic dysplasia 12.5
28 non-a-e hepatitis 12.5
29 renal-hepatic-pancreatic dysplasia 2 12.5
30 drug-induced hepatitis 12.5
31 hepatic fibrosis, severe due to schistosoma mansoni infection 12.5
32 porphyria, acute hepatic 12.4
33 renal-hepatic-pancreatic dysplasia 1 12.4
34 hepatic flexure cancer 12.4
35 hepatic coma 12.4
36 epstein-barr virus hepatitis 12.4
37 acute liver failure 12.4
38 granulomatous hepatitis 12.4
39 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 12.3
40 hepatitis, fulminant viral 12.3
41 glycogen storage disease iv 12.3
42 hepatitis b vaccine, response to 12.3
43 hepatic tuberculosis 12.3
44 hepatic infarction 12.3
45 halothane hepatitis 12.2
46 hepatic angiomyolipoma 12.2
47 hepatocellular carcinoma 12.2
48 sclerosing hepatic carcinoma 12.2
49 hepatic vascular disease 12.2
50 hepatic cystic hamartoma 12.2

Comorbidity relations with Hepatitis via Phenotypic Disease Network (PDN): (show all 14)

Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Cholangitis Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hepatic Encephalopathy
Hypothyroidism Mitral Valve Disease
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatitis:

Diseases related to Hepatitis

Symptoms & Phenotypes for Hepatitis

UMLS symptoms related to Hepatitis:

nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, hepatosplenomegaly, lameness, animal, icterus, dyspepsia, heartburn, gastrointestinal gas, hepatocellular jaundice

MGI Mouse Phenotypes related to Hepatitis:

# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.4 AFP ASGR2 CLDN1 HAVCR2 IFNAR2 KRT18

Drugs & Therapeutics for Hepatitis

Drugs for Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 884)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723 149351
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
Insulin glulisine Approved Phase 4 207748-29-6
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
Gliclazide Approved Phase 4 21187-98-4 3475
Glimepiride Approved Phase 4 93479-97-1 3476
Glyburide Approved Phase 4 10238-21-8 3488
Losartan Approved Phase 4 114798-26-4 3961
Promethazine Approved, Investigational Phase 4 60-87-7 4927
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
Simethicone Approved Phase 4 8050-81-5
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Colchicine Approved Phase 4 64-86-8 6167 2833
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
Fosamprenavir Approved Phase 4 226700-79-4 131536
Zidovudine Approved Phase 4 30516-87-1 35370
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
Didanosine Approved Phase 4 69655-05-6 50599
Citalopram Approved Phase 4 59729-33-8 2771
Meperidine Approved Phase 4 57-42-1 4058
Infliximab Approved Phase 4 170277-31-3
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
Halofantrine Approved Phase 4 69756-53-2 37393
Nelfinavir Approved Phase 4 159989-64-7 64143
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Metronidazole Approved Phase 4 443-48-1 4173
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
Pentetic acid Approved Phase 4 67-43-6
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
Baclofen Approved Phase 4 1134-47-0 2284
Propranolol Approved, Investigational Phase 4 525-66-6 4946

Interventional clinical trials:

(show top 50) (show all 4881)
# Name Status NCT ID Phase Drugs
1 Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults. Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
2 Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
3 PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab Unknown status NCT02523547 Phase 4 Cavir;Baraclude
4 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
5 Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study) Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
6 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
8 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
9 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
10 A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
11 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
12 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
13 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
14 Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir or Adefovir Monotherapy Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
15 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
16 A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Therapy for Patients Previously Treated in Dragon Study Unknown status NCT01829685 Phase 4 Entecavir, Adefovir
17 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
18 Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
19 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
20 Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
21 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
22 Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
23 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
24 A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Plus Adefovir Combination Treatment for Patients Previously Treated in EXPLORE, EXCEL and EFFORT Ex Study Unknown status NCT01834508 Phase 4 oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
25 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
26 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
27 A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy Unknown status NCT02594293 Phase 4 PegIFN alfa-2a
28 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
29 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
30 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
31 A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
32 A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response Unknown status NCT01056172 Phase 4 Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
33 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
34 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
35 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
36 HBsAg Clearance of Peginterferon Treatment in Patients Who Had Chronic Hepatitis B and Were on the Treatment of Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
37 The Changes of Natural Killer Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B. Unknown status NCT03208998 Phase 4 Peginterferon Alfa-2a
38 A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
39 The Changes of CD8+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B Unknown status NCT03209037 Phase 4 Peginterferon Alfa-2a
40 The Changes of CD4+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B Unknown status NCT03209011 Phase 4 Peginterferon Alfa-2a
41 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
42 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
43 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
44 A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
45 Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
46 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
47 A Randomized, Double Blind Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine With or Without Prednisolone Priming in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
48 Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4 Entecavir and peginterferon alfa-2a;Placebo and peginterferon
49 Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4 Entecavir and peginterferon (Pegasys) (52 weeks);Peginterferon (Pegasys) (96 weeks);Peginterferon (Pegasys) (48 weeks)
50 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg

Search NIH Clinical Center for Hepatitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Astragalus preparation
Milk thistle extract

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis:
Promethera HepaStem, human adult liver progenitor cells for liver diseases
Embryonic/Adult Cultured Cells Related to Hepatitis:
Adult liver progenitor cells PMIDs: 22525602 23211283 19091822 24142276 22900053

Cochrane evidence based reviews: hepatitis

Genetic Tests for Hepatitis

Genetic tests related to Hepatitis:

# Genetic test Affiliating Genes
1 Hepatitis 29

Anatomical Context for Hepatitis

MalaCards organs/tissues related to Hepatitis:

Liver, Testes, Kidney, T Cells, Bone, Skin, B Cells

Publications for Hepatitis

Articles related to Hepatitis:

(show top 50) (show all 31649)
# Title Authors PMID Year
Serum metabolome and targeted bile acid profiling reveals potential novel biomarkers for drug-induced liver injury. 17
31374067 2019
Drug-Induced Liver Injury - Types and Phenotypes. 17
31314970 2019
Fulminant acute hepatitis in pediatrics in Latin America and the Caribbean. 17
31340325 2019
Prevalence of hepatitis E virus infection in liver transplant recipients. 9 38
19790147 2009
Cytomegalovirus hepatitis and ganciclovir treatment in immunocompetent children. 9 38
18773667 2008
Does hepatitis C virus affect the reactivation of hepatitis B virus following renal transplantation? 9 38
16390851 2006
Role of hepatitis C virus in cardiomyopathies. 9 38
16329660 2006
Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. 9 38
16437641 2005
Autoimmune hepatitis triggered by acute hepatitis A. 9 38
16273628 2005
Hepatitis C virus core protein and hepatitis activity are associated through transactivation of interleukin-8. 9 38
15962221 2005
Prolonged acute hepatitis A mimicking autoimmune hepatitis. 9 38
15968741 2005
Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. 9 38
15756144 2005
Apoptosis pathway of liver cells in chronic hepatitis. 9 38
15457575 2004
Autoimmune hepatitis: evolving concepts. 9 38
15110233 2004
Coinfection of chronic hepatitis B and fasciolosis. 9 38
15007744 2004
Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. 9 38
15564749 2004
Safety of interferon beta treatment for chronic HCV hepatitis. 9 38
14695760 2004
[HFE gene mutations, hepatic iron content, and histological severity in hepatitis C virus-induced chronic hepatitis]. 9 38
14972004 2003
Does previous hepatitis A infection affect the clinicopathological status of chronic hepatitis C? 9 38
12845983 2003
Acute hepatitis associated with Barakol. 9 38
12930029 2003
[Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C]. 9 38
12501575 2002
Polyphyletic strains of hepatitis E virus are responsible for sporadic cases of acute hepatitis in Japan. 9 38
12202555 2002
Development of multicentric hepatocellular carcinoma after completion of interferon therapy. 9 38
12203085 2002
Hepatitis B surface antigenemia in chronic hemodialysis patients: effect of hepatitis B immunization. 9 38
11808938 2002
Therapeutic vaccination in chronic hepatitis B. 9 38
11895556 2002
Hepatitis B and C virus infection in Crohn's disease. 9 38
11720317 2001
Increased soluble P-selectin levels in hepatitis C virus-related chronic hepatitis: correlation with viral load. 9 38
11523696 2001
Combining hepatitis A and B vaccination in children and adolescents. 9 38
11257370 2001
GB virus B as a model for hepatitis C virus. 9 38
11406717 2001
Correlation of viral RNA, alanine aminotransferase, and histopathology in hepatitis C virus-associated hepatitis. 9 38
10553026 1999
Lamivudine for chronic delta hepatitis. 9 38
10421666 1999
Interferon-alpha in chronic hepatitis C infection in dialysis patients. 9 38
10401016 1999
The mouse interferon-gamma transgene chronic hepatitis model (Review). 9 38
10202184 1999
Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. 9 38
10363572 1999
Hepatitis virus infection in haemodialysis patients from Moldavia. 9 38
10052474 1999
[Drug-induced hepatitis]. 9 38
10647202 1999
Autoantibody to the liver arginase present in sera of patients with autoimmune hepatitis and chronic hepatitis. 9 38
10520898 1999
De novo hepatitis C in children after liver transplantation. 9 38
9721798 1998
Treatment of fibrosing cholestatic hepatitis with lamivudine. 9 38
9649474 1998
Phylogenetic analysis of hepatitis GB virus type C/hepatitis G virus in Spanish patients with chronic hepatitis B or C virus infection. 9 38
10325532 1998
Prediction of effect of interferon on chronic hepatitis C. 9 38
9398805 1997
Efficacy of interferons in treating children with chronic hepatitis C. 9 38
9296534 1997
Plasma collagen-binding vitronectin activated by heparin and dextran sulfate in chronic liver disease. 9 38
9387191 1997
Granulomatous hepatitis in a patient with chronic hepatitis C treated with interferon-alpha. 9 38
9246044 1997
Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. 9 38
9210606 1997
Expression of IFN-inducible protein-10 in chronic hepatitis. 9 38
9164978 1997
[Interferon treatment for hepatitis G virus infection in patients with chronic hepatitis C]. 9 38
9086771 1997
Changes in results of Gallium-67-citrate scanning after interferon therapy for chronic hepatitis C. 9 38
9025739 1997
Nucleotide sequence diversity of hypervariable region 1 of hepatitis C virus in Japanese hemophiliacs with chronic hepatitis C and patients with chronic posttransfusion hepatitis C. 9 38
8695870 1996
Hepatitis C virus infection in health care workers referred to a hepatitis clinic. 9 38
8657027 1996

Variations for Hepatitis

ClinVar genetic disease variations for Hepatitis:

# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 MT:3275-3275 MT:3275-3275

Copy number variations for Hepatitis from CNVD:

# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 226111 7 55054218 55242525 Amplification EGFR Hepatitis

Expression for Hepatitis

Search GEO for disease gene expression data for Hepatitis.

Pathways for Hepatitis

Pathways related to Hepatitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.74 IFNAR2 IFNA2 IFNA1
2 10.54 SCARB1 LMBRD1
Show member pathways
10.32 IFNAR2 IFNA2

GO Terms for Hepatitis

Biological processes related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.46 IFNL4 IFNAR2 IFNA2 IFNA1
2 T cell activation involved in immune response GO:0002286 9.43 IFNA2 IFNA1
3 type I interferon signaling pathway GO:0060337 9.43 IFNAR2 IFNA2 IFNA1
4 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.4 IFNA2 IFNA1
5 natural killer cell activation involved in immune response GO:0002323 9.37 IFNA2 IFNA1
6 hepatocyte apoptotic process GO:0097284 9.32 KRT8 KRT18
7 viral entry into host cell GO:0046718 9.26 SLC10A1 SCARB1 HAVCR1 CLDN1
8 viral process GO:0016032 9.17 SLC10A1 SCARB1 LMBRD1 KRT8 KRT18 HAVCR1

Molecular functions related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.16 IFNA2 IFNA1
2 type I interferon receptor binding GO:0005132 8.96 IFNA2 IFNA1
3 virus receptor activity GO:0001618 8.92 SLC10A1 SCARB1 HAVCR1 CLDN1

Sources for Hepatitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA